M&T Bank’s Biogen BIIB Stock Holding History

M&T Bank’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-400	Closed	-$20K	–	2105
2015 Q1	$20K	Hold	400	–	–	﹤0.01%	1964
2014 Q4	$7K	Buy	+400	New	+$129K	﹤0.01%	2053

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

M&T Bank's BIIB Position: Q1 2026 in Review

M&T Bank reduced its Biogen (BIIB) stake by 5.6% in Q1 2026, selling an estimated $174K and leaving 15,817 shares worth $2.9M. The position accounts for 0.01% of the portfolio, ranked #505.

M&T Bank first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $32.6M in Q1 2015. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

M&T Bank held 15,817 shares of Biogen worth $2.9M as of Q1 2026.
M&T Bank sold 944 Biogen shares in Q1 2026, an estimated $174K.
Biogen made up 0.01% of M&T Bank's portfolio in Q1 2026, its #505 holding.
M&T Bank first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
M&T Bank's Biogen position peaked at $32.6M in Q1 2015.
1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on M&T Bank's 13F filing for Q1 2026, filed 12 May 2026.